Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Oyster Point Pharmaceuticals

Request full access

A clinical stage pharmaceutical company focused on the discovery development & commercialization

San Francisco, United StatesFounded 2015Biotech & Life Sciences

About Oyster Point Pharmaceuticals

Oyster Point Pharmaceuticals operated as a commercial-stage biopharmaceutical company, directing its efforts toward the discovery, development, and commercialization of treatments for ophthalmic diseases. The company was founded in 2015 and established its headquarters in Princeton, New Jersey. Michael Ackermann co-founded the company in 2017 after identifying a significant unmet need for dry eye disease treatment during a Stanford Innovation Fellowship. Jeffrey Nau, who has over two decades of experience in the biopharma sector, joined as the first employee and CEO in 2017. His background includes key roles at Genentech, where he was involved in the development of Lucentis, a treatment for blinding eye conditions. Nau guided Oyster Point through an initial public offering in 2019 and oversaw its acquisition by Viatris in early 2023.

The company's business was centered on its flagship product, TYRVAYA® (varenicline solution) Nasal Spray, which received FDA approval in October 2021. This prescription-based product is the first and only nasal spray for treating the signs and symptoms of dry eye disease, a chronic and progressive condition affecting a large patient population. The business model revolves around the sale of TYRVAYA to patients through prescriptions from eye care professionals. By July 2022, the product had secured commercial coverage for approximately 117 million people in the U.S. Revenue is generated from the net product sales, with the company reporting $5.6 million in the third quarter of 2022.

TYRVAYA offers a distinct approach to treating dry eye disease by avoiding direct application to the ocular surface. It is a highly selective cholinergic agonist administered as a twice-daily nasal spray. The product is believed to work by binding to cholinergic receptors in the nose to activate the trigeminal parasympathetic pathway, which stimulates the glands and cells responsible for producing natural tear film. This mechanism helps the body increase its own basal tear production. In clinical trials involving over 1,000 patients, approximately half of those treated with TYRVAYA demonstrated a significant increase in tear production compared to control groups. The most common side effect reported was sneezing. The product is supplied in cartons of two multi-dose spray bottles, providing a 30-day supply. Following its acquisition, Oyster Point Pharma now forms the foundation of Viatris's new ophthalmology franchise, with Jeffrey Nau leading the division.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019
Employees
28
Open positions
None listed
Dealroom signal
27.6/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Dec 2022 $415M $415M Viatris ↗
POST IPO EQUITYOther financing May 2020 $121M — Undisclosed ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Oyster Point Pharmaceuticals website traffic

Latest recorded traffic for Oyster Point Pharmaceuticals is 490 monthly website visits, down 40.2% over the last three months. Oyster Point Pharmaceuticals's team declined 58.2% over the past year.

Latest monthly visits490 3-month web change-40.2% 1-year team growth-58.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Oyster Point Pharmaceuticals in the San Francisco ecosystem

Live from Dealroom

The Oyster Point Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Other known investors3 additional known investors

Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Oyster Point Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Oyster Point Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.